Track market-moving stories before they get noisy

NOTTINGHAM, England--(BUSINESS WIRE)-- #AgilentTechnologies--Multimillion dollar investment round to enable HALO to complete regulatory approval of its advanced security screening technology.

Key Takeaways Agilent is expanding its AI software and automation portfolio to support its biopharma growth prospects. Agilent launched xCELLigence RTCA eSight AI to simplify label-free live-cell imaging analysis. A expects fiscal Q3 2026 revenues of $1.83B-$1.85B, implying 5.0%-6.5% reported growth. Agilent Technologies (A - Free Report) shares have lost 5.2% in the year-to-date period, underperforming the Zacks Medical  industry's 2.8% growth. The dip reflects cautious laboratory spending and a challenging macroeconomic environment.

However, Agilent continues to strengthen its long-term growth prospects through product innovation and expanding artificial intelligence (AI)-enabled laboratory software and automation capabilities, supported by healthy demand across the pharmaceutical, diagnostics and advanced materials markets.

The company also benefits from growing demand for AI-enabled laboratory software and automation as pharmaceutical and biotechnology companies increasingly digitize research workflows and accelerate drug discovery. Agilent's integrated software ecosystem, led by its OpenLab and xCELLigence platforms, combines analytical instruments, software and laboratory automation to improve productivity, reduce manual intervention and deliver more consistent scientific results.

Agilent Expands AI-Powered Cell Analysis PortfolioAgilent continues to strengthen its AI-enabled laboratory portfolio through innovations spanning analytical instruments, laboratory software, automation and digital workflows, supporting the growing adoption of AI-driven research solutions.

Building on this strategy, the company launched xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free live-cell imaging analysis. The software enhances the xCELLigence RTCA eSight platform by combining AI-driven image analysis with impedance measurements, enabling researchers to analyze imaging and cell behavior simultaneously from the same experiment.

The new module replaces manual cell segmentation and subjective parameter tuning with a one-click automated workflow, helping researchers generate more consistent and reproducible results while reducing analysis time and lowering training requirements. Designed for drug discovery and high-throughput biopharma research, the software is expected to accelerate scientific workflows, improve laboratory productivity and expand adoption of Agilent's integrated cell analysis platform, supporting long-term software and biopharma growth.

AI Innovation Strengthens Agilent's Growth StoryAgilent continues to expand its AI capabilities across laboratory software, automation and digital workflows. During the second quarter of fiscal 2026, AI was highlighted as a key long-term growth driver, with increasing customer adoption and continued investments in digital laboratory solutions expected to support sustainable growth. Agilent is integrating AI across its analytical instruments, laboratory informatics and automation solutions to enhance scientific workflows and operational efficiency.

Agilent is further expanding its digital laboratory capabilities through its announcement of the China Innovation Center in June 2026, which focuses on AI, automation and digital laboratory technologies to enable next-generation smart laboratories. These initiatives strengthen Agilent's AI-enabled laboratory portfolio and are expected to address growing demand for AI-powered laboratory software and automation solutions, strengthening the company's long-term growth prospects.

Agilent Provides Strong Fiscal Q3 2026 OutlookAgilent's improving demand environment, expanding AI software portfolio and continued product innovation are expected to benefit the company’s top-line growth.

For the third quarter of fiscal 2026, A expects revenues to be in the range of $1.83-$1.85 billion, implying 5.0%-6.5% reported growth and 4.4%-5.9% core growth.

The Zacks Consensus Estimate for third-quarter fiscal 2026 revenues is pegged at $1.84 billion, indicating year-over-year growth of approximately 6.02%.

The consensus estimate for third-quarter fiscal 2026 earnings is pegged at $1.47 per share, which has decreased by a penny over the past 30 days, indicating year-over-year growth of 7.30%.

A’s Zacks Rank & Stocks to ConsiderCurrently, Agilent carries a Zacks Rank #3 (Hold).

Fortrea Holdings Inc (FTRE - Free Report) , Neurocrine Biosciences (NBIX - Free Report) and PTC Therapeutics (PTCT - Free Report) are some better-ranked stocks that investors can consider in the broader Zacks Medical sector. Fortrea Holdings Inc, Neurocrine Biosciences and PTC Therapeutics sport a Zacks Rank #1 (Strong Buy) each at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

FTRE shares have lost 1.4% in the year-to-date period. The long-term earnings growth rate for Fortrea Holdings is pegged at 40.91%.

NBIX shares have risen 25.6% in the year-to-date period. The long-term earnings growth rate for Neurocrine Biosciences is pegged at 33.41%.

Shares of PTCT have gained 16.6% in the year-to-date period. The long-term earnings growth rate for PTC Therapeutics is pegged at 27.74%.

[url="]Alpha and Omega Semiconductor Limited[/url] (AOS) (Nasdaq: AOSL), a designer, developer, and global supplier of a broad range of discrete power devices,

It has been about a month since the last earnings report for Agilent Technologies (A - Free Report) . Shares have added about 0.1% in that time frame, outperforming the S&P 500.

Will the recent positive trend continue leading up to its next earnings release, or is Agilent due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important drivers.

Agilent Technologies Q2 Earnings Beat Estimates, Revenues Up Y/YAgilent Technologies reported second-quarter fiscal 2026 earnings of $1.49 per share, up 13.7% year over year. The figure surpassed the Zacks Consensus Estimate by 6.21%.

Quarterly revenues came in at $1.84 billion, which represented 10% reported growth year over year. The figure beat the Zacks Consensus Estimate by 2.12%. Strength in instruments and solid execution also supported a favorable mix, with 66% of fiscal second-quarter revenue coming from recurring streams such as consumables, services and informatics.

A Posts Strong Q2 Growth Across Operating SegmentsA’s top-line expansion was broad-based across its three reporting groups. The Life Sciences and Diagnostics Markets Group generated $732 million of revenues, up 12% year over year on a reported basis and 9% on a core basis.

Agilent CrossLab delivered $759 million, reflecting 6% reported growth and 2% core growth, while Applied Markets recorded $344 million, increasing 14% reported and 11% core. Segment profitability remained solid, with operating margins of 22.0% in LDG, 32.0% in CrossLab and 23.3% in Applied Markets.

Agilent’s Q2 Operating ResultsFor the second quarter of fiscal 2026, the LDG segment’s gross margin expanded 130 basis points (bps) year over year to 54.1%. ACG’s gross margin was flat year over year to 55.5%, while AMG’s gross margin expanded 230 bps year over year to 55.8%.

Research and development (R&D) expenses on a non-GAAP basis were $116 million, up 6.4% from the prior-year quarter. Selling, general, and administrative (SG&A) expenses on a non-GAAP basis rose to $409 million, marking a 9.4% increase from the prior-year quarter.

As a percentage of revenues, R&D expenses fell 20 bps year over year to 6.3%, while SG&A expenses fell 10 bps year over year to 22.3%.

Non-GAAP operating margin expanded 130 basis points year over year to 26.4% and improved 180 basis points sequentially.

A Sees Divergent Trends Across End MarketsDemand trends varied by end market, but the overall mix remained constructive. Pharma, which represented 36% of quarterly revenues, delivered 6% core growth and marked a fifth straight quarter of mid-single to low-double-digit growth, including low-double-digit growth in biotech.

Diagnostics and Clinical (16% of revenue) rose 11% on core growth, supported by expansion in Cancer Diagnostics offerings and traction for the Omnis family. Chemicals and Advanced Materials (23% of revenue) increased 8%, driven by semiconductor demand and chemicals capex investments in the Americas, while Environmental and Forensics (10% of revenue) grew 13% on competitive wins and a TSA airport security contract. Offsetting pockets of strength, Academia and Government (7% of revenue) declined 5% amid a muted research funding environment, and Food (8% of revenue) fell 3% on funding delays in China and India.

Agilent Details Geography and Business Mixeographically, results reflected strength in the Americas and Europe and a tougher year-over-year comparison in Asia-Pacific. Core revenue growth was 11% in the Americas and 8% in Europe, while APAC declined 1% on a core basis. In terms of mix, the Americas accounted for 42% of Agilent’s fiscal second-quarter revenue, Europe contributed 28% and APAC represented 30%.

Agilent also highlighted the durability of its model through the product-type mix. Consumables, services and informatics represented 66% of total revenues in the quarter, while instruments accounted for the remaining 34%. The company emphasized robust instrument growth in the quarter alongside an increasing recurring-revenue mix.

A’s Balance Sheet DetailsThe balance sheet remained steady. Cash and cash equivalents totaled $1.807 billion as of April 30, 2026, compared with $1.75 billion as of Jan. 31, 2025, while long-term debt stood at $3.051 billion.

Agilent generated $277 million in operating cash flow during the quarter and returned cash to shareholders through multiple channels. The company spent $65 million to repurchase 0.55 million shares and paid $72 million in dividends, along with $76 million of capex investment.

A Raises Full-Year Outlook and Issues Q3 TargetsA lifted its fiscal 2026 outlook, driven by increased confidence in business performance and execution. Full-year revenues are now expected to be in the range of $7.39-$7.49 billion, with core revenue growth projected to be between 4.5% and 6.0%. The company also expects 85 basis points of non-GAAP operating margin expansion at the midpoint of core growth guidance.

For the third quarter of fiscal 2026, A expects revenues in the range of $1.83-$1.85 billion, implying 5.0%-6.5% reported growth and 4.4%-5.9% core growth. Non-GAAP earnings for the quarter are expected to be in the range of $1.48-$1.50 per share, while full-year non-GAAP earnings were raised to $6.00-$6.10 per share.

How Have Estimates Been Moving Since Then?In the past month, investors have witnessed a downward trend in estimates review.

VGM ScoresCurrently, Agilent has a subpar Growth Score of D, a score with the same score on the momentum front. Following the exact same course, the stock was allocated a score of D on the value side, putting it in the bottom 40% for this investment strategy.

Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Interestingly, Agilent has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

Denver, CO and London, UK – 25 June 2026: Excellere Partners (“Excellere”), a Denver-based private equity firm specializing in partnering with entrepreneurs and management teams, and GHO Capital Partners LLP (“GHO”), a specialist investor in global healthcare, today announced the completion of the sale of Biocare Medical ("Biocare"), a global leader in immunohistochemistry (IHC), in situ hybridization (ISH) and fluorescence in situ hybridization (FISH) solutions, to Agilent Technologies, Inc. ("Agilent", NYSE:A).

Under the stewardship of Excellere and GHO, the company delivered annual double-digit revenue and profitability growth, strengthened its core IHC business, expanded into molecular diagnostics through acquisition, and reinforced its executive leadership team. Biocare has since become a recognised specialist in IHC, ISH and FISH, with a high-quality antibody business and strong commercial, regulatory and R&D capabilities.

Agilent's acquisition of Biocare brings together two businesses with closely aligned strategies in life sciences and diagnostics. The combination is expected to unlock greater market access, enhanced customer support and accelerated innovation for Biocare's customers worldwide.

In a joint statement, Excellere and GHO said: “This transaction marks a significant milestone for Biocare and a strong outcome for our portfolios. Working closely with Luis and the management team, we applied our growth playbook and deep sector expertise, to help build a company with genuine transatlantic reach and a leading position in IHC solutions. We are delighted to have found the right partner in Agilent to support Biocare’s next phase of growth and are confident that its global reach and resources will deliver even greater value for customers and, ultimately, the patients they serve.”

-Ends-

Further information:

Excellere Partners media enquiries
Tracie Kelly
Tel: +1 (303)-765-2374
[email protected]

GHO Capital Partners LLP
T +44 20 3700 7440
E [email protected]

About Excellere Partners

Excellere Partners is a Denver-based private equity firm with $2.3 billion of committed capital across four funds that specialize in partnering with entrepreneurs and management teams through growth recapitalizations and management buyouts. The firm employs a research-driven, top-down investment strategy and supports its entrepreneurs and management teams with a proprietary value-creation process designed to enhance the corporate and operational infrastructure for scalability and growth. Excellere’s investments are focused on emerging growth companies positioned to benefit from industry consolidation and favorable macroeconomic and demographic trends. The Firm’s targeted industry sectors include healthcare, industrial growth, and business services. For more information about Excellere, please visit  https://www.excellere.com

About GHO Capital

Global Healthcare Opportunities, or GHO Capital Partners LLP, is a leading specialist healthcare investment advisor based in London. We apply global capabilities and perspectives to unlock high growth healthcare opportunities, targeting Pan-European and transatlantic internationalisation to build market leading businesses of strategic global value. Our proven investment track record reflects the unrivalled depth of our industry expertise and network. We partner with strong management teams to generate long-term sustainable value, improving the efficiency of healthcare delivery to enable better, faster, more accessible healthcare.

In May 2026, GHO Capital announced its combination with CBC Group, creating the world’s largest dedicated healthcare investment manager with over $21 billion in AUM. The transaction is expected to close in early 2027, subject to customary closing conditions and regulatory approvals.

For further information, please visit www.ghocapital.com.

About Biocare Medical

Biocare Medical is a global leader in immunohistochemistry (IHC) and molecular pathology solutions, offering automated instrumentation, high-quality reagents, and simultaneous multiplexing to advance cancer diagnostics and research. Biocare’s mission is to deliver advanced staining solutions designed to produce the highest-quality image on every slide, driving diagnostic accuracy and creating a digital-ready platform for the future of pathology.

NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- SueWallSt reminds purchasers of Microsoft Corporation (NASDAQ: MSFT) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased Microsoft securities between May 1, 2025 and January 28, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify for recovery or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

Microsoft shares traded above $550 during the Class Period as the Company promoted Copilot as a transformative enterprise AI product with "best-in-class" capabilities. The lead plaintiff deadline is August 11, 2026.

How an Enterprise AI Product Generates Revenue

An enterprise software company cannot sustain premium pricing for AI-powered productivity tools unless those tools deliver measurable workflow improvements, integrate seamlessly with existing systems, and retain users after initial deployment. Microsoft's Copilot family of products was positioned as exactly this kind of tool, embedded across Word, Excel, PowerPoint, Outlook, and Teams, and sold through paid "seats" to businesses worldwide. Management claimed Copilot was the "fastest-growing M365 portfolio product" ever, with paid commercial seats exceeding 430 million and adoption by over 90% of the Fortune 500.

The lawsuit contends that behind these adoption figures, Copilot suffered from fundamental operational failures that undermined its commercial viability.

Alleged Copilot Product Deficiencies by Category

The action claims Microsoft failed to disclose that Copilot experienced serious problems across multiple operational dimensions:

Brand positioning failures: Copilot's identity was fragmented across dozens of product versions with different features and capabilities, confusing both enterprise buyers and end usersUser experience deficiencies: The product allegedly failed to meet baseline expectations for generative AI writing, analysis, and content creation that management called "table stakes"Data siloing problems: Despite touting "Work IQ" as a differentiator that understood users' work context, Copilot allegedly could not effectively integrate data across Microsoft's own application ecosystemComputational capacity constraints: Microsoft was increasing total AI capacity by 80% and doubling its data center footprint, yet the filing asserts capacity remained insufficient to deliver consistent Copilot performanceInteroperability breakdowns: Copilot's integration with third-party ISV agents and enterprise workflows allegedly fell short of the seamless orchestration management described at investor conferences
The Operational Gap Between Claims and Alleged Reality

As detailed in the action, management portrayed Copilot as saving employees an average of 46 minutes daily at one major deployment and generating over 30 million employee interactions in six months at another. The complaint asserts these cherry-picked examples masked systemic product shortcomings that threatened the sustainability of seat growth and ARPU expansion that drove Microsoft's AI revenue narrative.

The filing states that organizational problems within Microsoft's AI division compounded these product-level issues, creating internal friction that slowed Copilot's development and deployment capabilities even as management publicly claimed innovation was "accelerating rapidly."

Start your claim now or call (888) SueWallSt.

"The complaint raises serious questions about whether investors received accurate information about the operational readiness of Microsoft's flagship AI product during a period when the Company was asking the market to value it as an AI leader," stated Joseph E. Levi, Esq.

Investors have until August 11, 2026 to seek lead plaintiff status.

SueWallSt -- Top 50 securities litigation firm (ISS, seven consecutive years). Over 70 professionals. Hundreds of millions recovered.

Frequently Asked Questions About the MSFT Lawsuit

Q: Who is eligible to join the MSFT investor lawsuit? A: Investors who purchased MSFT stock or securities between May 1, 2025 and January 28, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: What specific misstatements does the MSFT lawsuit allege? A: The complaint alleges Microsoft made materially false or misleading statements regarding the success, adoption, and operational performance of its Copilot AI products while concealing significant brand positioning, data siloing, computational capacity, and interoperability problems. When the true state was revealed, the stock price declined.

Q: What do MSFT investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my MSFT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

CONTACT:

SueWallSt

Joseph E. Levi, Esq.

33 Whitehall Street, 27th Floor

New York, NY 10004

[email protected]

Tel: (888) SueWallSt

Fax: (212) 363-7171

Freehold, NJ, June 24, 2026 (GLOBE NEWSWIRE) -- UMH Properties, Inc. (NYSE: UMH) (TASE: UMH), a real estate investment trust (REIT) specializing in manufactured home communities, today expressed strong support for the 21st Century ROAD to Housing Act, comprehensive bipartisan legislation designed to address the nation’s housing shortage by expanding supply, reducing costs, and modernizing regulations for manufactured housing.

Samuel A. Landy, President and Chief Executive Officer of UMH commented “Manufactured homes provide high-quality, affordable housing options for millions of American families, and this legislation removes outdated barriers that have limited their potential. By modernizing federal standards, the ROAD to Housing Act will lower production costs, improve financing access, and ease placement restrictions, enabling UMH to expand our communities, enhance resident offerings, and deliver even greater value to our shareholders and the families we serve. These reforms are poised to accelerate industry growth, complementing UMH’s ongoing initiatives in community development, home sales, and operational excellence. The Act includes key provisions that the Company believes will significantly benefit the manufactured housing sector and UMH’s portfolio of communities across the Northeast, Southeast, and Midwest. With 145 communities and 27,100 homesites, UMH is well-positioned to capitalize on increased demand for affordable, high-quality housing solutions.

“Improvements to the Title One financing program should allow more people to qualify for financing and achieve the American dream of home ownership, thereby increasing sales of homes that qualify for the program. Additionally, with the removal of the chassis requirement, we will be able to introduce a broader range of home designs and anticipate being able to increase the square footage of each home by utilizing multi-story homes. Building two residential units on one lot with one structure should reduce the cost of housing and increase the revenue per lot. The new law encourages zoning for innovative affordable housing which UMH provides.

“UMH remains committed to providing safe, well-maintained communities and supporting the American Dream of homeownership through manufactured housing.

“I would like to thank the Manufactured Housing Institute for their hard work advocating for our industry and their efforts to adopt this bill.”

Lesli Gooch, PH. D., Chief Executive Officer of the Manufactured Housing Institute commented “We commend Congress and the Administration for advancing this landmark housing package and recognizing the critical role manufactured housing has in addressing the nation’s housing supply challenges. This bill will expand the range of homes that can be built under the federal residential construction code, make it easier to site manufactured homes where they are most needed, and improve financing options for small dollar loans for manufactured homes. In short, the bill will be a shot in the arm to help high-quality manufactured homes make attainable homeownership possible for more families across the country.”

Key Benefits for Manufactured Housing and UMH Properties Include:

Removal of the Permanent Chassis Requirement: The legislation updates the federal definition of a “manufactured home” to allow units “with or without a permanent chassis.” This change is expected to reduce construction costs by thousands per home, enable innovative multi-story designs, larger floor plans, and more flexible installation options such as slab-on-grade or placement over basements. It also promotes uniformity in state laws for financing, titling, taxation, and zoning treatment, making manufactured homes more competitive in a broader range of locations, including urban infill sites.

Updates to FHA Title I Financing: Through the Property Improvement and Manufactured Housing Loan Modernization Act, the bill increases loan limits for FHA-insured manufactured housing and property improvement loans, expands eligible uses (including accessory dwelling units), and directs studies to further reduce barriers. These enhancements should improve affordability and accessibility for potential homebuyers, supporting higher occupancy and sales growth in our communities.

Easing of Zoning and Land-Use Barriers: Broader provisions in the Act promote housing supply through incentives for local governments, guidelines for zoning reforms, and support for factory-built housing. Combined with the chassis reform, this creates a more favorable environment for placing manufactured homes in diverse residential areas, aligning with UMH’s growth strategy in established and expanding markets.

UMH Properties, Inc., which was organized in 1968, is a public equity REIT that owns and operates 145 manufactured home communities, containing approximately 27,100 developed homesites, of which 11,200 contain rental homes, and over 1,000 self-storage units. These communities are located in New Jersey, New York, Ohio, Pennsylvania, Tennessee, Indiana, Maryland, Michigan, Alabama, South Carolina, Florida and Georgia. Included in the 145 communities are two communities in Florida, containing 363 sites, and one community in Pennsylvania, containing 113 sites, that UMH has an ownership interest in and operates through its joint ventures with Nuveen Real Estate.

Certain statements included in this press release which are not historical facts may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements are based on the Company’s current expectations and involve various risks and uncertainties. Although the Company believes the expectations reflected in any forward-looking statements are based on reasonable assumptions, the Company can provide no assurance those expectations will be achieved. The risks and uncertainties that could cause actual results or events to differ materially from expectations are contained in the Company’s annual report on Form 10-K and described from time to time in the Company’s other filings with the SEC. The Company undertakes no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.

Contact:Nelli Madden 732-577-4062

23.87K Followers

Analyst’s Disclosure: I/we have a beneficial long position in the shares of CAR.UN:CA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Sportradar's SEC Filings Acknowledged Regulatory Risks in Generic Terms While the Company Allegedly Operated a Black-Market Revenue Pipeline Spanning Six Prohibited Countries

, /PRNewswire/ -- Levi & Korsinsky, LLP reminds purchasers of Sportradar Group AG (NASDAQ: SRAD) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased SRAD securities between November 7, 2024, and April 21, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify to recover your per-share losses or contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.

Shares fell $3.80 per share, a 22.6% single-day decline, after investigative reports on April 22, 2026, revealed the alleged scope of Sportradar's illegal gambling operator relationships. The last day to move for lead plaintiff is July 17, 2026.

What the Company Disclosed in SEC Filings

Across its 2023, 2024, and 2025 Annual Reports, Sportradar included risk factor language acknowledging it was "subject to a variety of U.S. and foreign laws on sports betting" and that "the legality of sports betting is subject to uncertainties." Each filing confirmed that the Company had "obtained all licenses, authorizations, findings of suitability, registrations, permits and approvals necessary for our current operations." These filings were signed and certified by senior executives.

The complaint challenges whether these disclosures were adequate given what investigators later uncovered.

What the Lawsuit Alleges Was Missing

The securities action contends that Sportradar's boilerplate risk warnings omitted critical, specific information that the Company already knew:

Over 270 individual platforms using Sportradar products were allegedly operating illegally in regulated or prohibited gambling markets, representing more than a third of the 800 clients the Company claimed to serve Sales executives allegedly walked undercover investigators through product offerings tailored for illegal markets in Vietnam, Thailand, Indonesia, and China A top-ten client, 1xBet, was described by former employees as "likely the world's largest illegal gambling operator by revenue" The Company allegedly maintained direct connections to operators in Russia, Turkey, and multiple Asian jurisdictions that forbid online gaming Three regulators in North America and Europe have reportedly commenced reviews following the investigative findings Why Generic Risk Language May Not Shield the Company

The complaint argues that Sportradar's disclosures framed illegal-market exposure as a hypothetical possibility while the Company was allegedly engaged in those markets as a core business strategy. The filing states that generic warnings about regulatory uncertainties cannot substitute for disclosing that the Company was already deriving material revenue from operators it knew were illegal. When Sportradar certified it had obtained "all licenses necessary for current operations," the lawsuit maintains this was misleading because it omitted that the Company's partners were operating without required licenses in prohibited jurisdictions.

"Generic risk factor language cannot substitute for disclosing specific, known problems that are already affecting a company's operations. The gap between what Sportradar's filings warned about hypothetically and what was allegedly happening operationally raises serious questions for shareholders." -- Joseph E. Levi, Esq.

Join the SRAD recovery action or call Joseph E. Levi, Esq. at (212) 363-7500.

ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report.

Frequently Asked Questions About the SRAD Lawsuit

Q: What specific misstatements does the SRAD lawsuit allege? A: The complaint alleges Sportradar made materially false or misleading statements regarding its compliance processes, KYC procedures, and the legality of its client relationships during the class period. When investigative reports revealed the Company's alleged ties to over 270 illegal gambling platforms, the stock price declined sharply.

Q: When did Sportradar allegedly mislead investors? A: The class period runs from November 7, 2024, to April 21, 2026. The alleged fraud was revealed on April 22, 2026, through reports by Muddy Waters Research and Callisto Research, causing a 22.6% stock decline.

Q: What do SRAD investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my SRAD shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

CONTACT:

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171 

SOURCE Levi & Korsinsky, LLP

Alert: Claims Focus on Alleged Misrepresentations About Regencell's $1 Million R&D Budget Versus $14 Billion Market Valuation

, /PRNewswire/ -- SueWallSt reminds purchasers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities of a pending securities class action.

THE CASE: A class action was filed, seeking to recover damages for investors who purchased Regencell securities between October 28, 2024 and October 31, 2025.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

Regencell's ordinary shares fell $3.09 per share, or 18.56%, to close at $13.56 on November 3, 2025, after the Company disclosed a U.S. Department of Justice subpoena and investigation into trading in its shares. Investors have until June 23, 2026 to seek lead plaintiff status.

A Bioscience Company Without Revenue or Approved Products

A bioscience company cannot bring a drug to market without sustained, large-scale research investment. The complaint recounts that Regencell spent approximately $0.95 million on research and development for the fiscal year ended June 30, 2025, and $1.07 million for the prior year. These figures are striking given that Regencell's own SEC filings acknowledged that the average cost to bring a new medicine from R&D to marketplace is "nearly $4 billion, and can sometimes exceed $10 billion." Despite this admitted gap, the Company carried a market valuation of approximately $14 billion.

The Alleged $14 Billion Valuation Disconnected From Fundamentals

As detailed in the action, Regencell operated with twelve employees, generated zero revenue, had no approved or salable products, and had incurred operating losses since its formation. Yet its share price surged from under $0.30 to a Class Period high of $78.00 per share on June 17, 2025, representing a 48,650% increase. The Wall Street Journal noted in January 2026 that only 20 of the 261 companies in the Nasdaq Biotechnology Index had a greater market value than Regencell.

Alleged Operational Disconnects by the Numbers

Regencell's total R&D spend across both fiscal years was approximately $2.02 million combined, while its own filings stated new drug development costs average $4 billion to $10 billion The Company employed just twelve people while pursuing treatments for ADHD and ASD, conditions widely considered incurable under current medical consensus Regencell generated no revenue and had no products approved for sale at any point during the Class Period Defendant Yat-Gai Au held 88.6% of outstanding shares, leaving a minimal public float A 38-for-1 stock split in June 2025 was described as intended to "enhance liquidity" and "make the shares more accessible to investors," yet the share price nearly quadrupled in the days surrounding the split The Company's $14 billion market valuation exceeded that of the vast majority of companies in the Nasdaq Biotechnology Index Calculate your potential recovery or call (888) SueWallSt.

"The complaint raises serious questions about whether investors received accurate information regarding the fundamental disconnect between Regencell's operational scale and the extraordinary valuation its shares commanded during the Class Period," stated Joseph E. Levi, Esq.

SueWallSt represents shareholders in securities class actions nationwide, with a track record of recovering hundreds of millions for investors. Over 70 professionals. Ranked among ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the RGC Lawsuit

Q: Who is eligible to join the RGC investor lawsuit? A: Investors who purchased RGC stock or securities between October 28, 2024 and October 31, 2025 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did RGC stock drop? A: Shares fell approximately 18.56%, a decline of $3.09 per share, after the Company disclosed a DOJ subpoena and investigation into trading in its ordinary shares. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What do RGC investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my RGC shares, can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.

CONTACT:

SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

iShares US Large Cap Premium Income Active ETF (BALI) targets conservative, income-focused investors seeking high yield with lower volatility than the broader market. BALI offers a 7.8% distribution yield and a low 0.35% expense ratio, outperforming some covered call peers in recent periods while maintaining a conservative cost structure. The ETF's options overlay strategy caps upside, leading to underperformance in strong bull markets and heightened risk of NAV decline and payout volatility in prolonged bear markets.

Agilent Technologies (A - Free Report) came out with quarterly earnings of $1.49 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.31 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +6.21%. A quarter ago, it was expected that this scientific instrument maker would post earnings of $1.37 per share when it actually produced earnings of $1.36, delivering a surprise of -0.73%.

Over the last four quarters, the company has surpassed consensus EPS estimates two times.

Agilent, which belongs to the Zacks Medical - Products industry, posted revenues of $1.84 billion for the quarter ended April 2026, surpassing the Zacks Consensus Estimate by 2.12%. This compares to year-ago revenues of $1.67 billion. The company has topped consensus revenue estimates three times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Agilent shares have lost about 15.4% since the beginning of the year versus the S&P 500's gain of 9.8%.

What's Next for Agilent?While Agilent has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Agilent was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is $1.50 on $1.83 billion in revenues for the coming quarter and $5.95 on $7.38 billion in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Products is currently in the bottom 35% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

Another stock from the same industry, Canopy Growth Corporation (CGC - Free Report) , has yet to report results for the quarter ended March 2026. The results are expected to be released on June 15.

This company is expected to post quarterly loss of $0.06 per share in its upcoming report, which represents a year-over-year change of +93.6%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days.

Canopy Growth Corporation's revenues are expected to be $53.26 million, up 17.6% from the year-ago quarter.

Hims & Hers Eyes Global Growth: Will $1.15B Eucalyptus Deal Fuel Its Recovery or Dilute Shareholders?Agilent Technologies NYSE: A raised its fiscal 2026 outlook after reporting stronger-than-expected second-quarter results, with management pointing to broad-based demand, instrument replacement momentum, pricing actions and operational gains from its Ignite operating system.

CEO Padraig McDonnell said Agilent delivered “an excellent second quarter” with revenue of $1.83 billion, up 6.3% on a core basis and above the high end of the company’s guidance. Non-GAAP operating margin expanded to 26.4%, up 130 basis points from a year earlier, while non-GAAP earnings per share rose 14% to $1.49, exceeding the top end of guidance by $0.07.

Get Agilent Technologies alerts:

Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak“We delivered at or above our long-term plan on all metrics, revenue growth, margin expansion and EPS growth,” McDonnell said. He said the quarter showed that benefits from the company’s Ignite operating system are becoming “structurally embedded” in the business.

Key End Markets Show Broad Strength McDonnell said Agilent’s performance was supported by strength across several of its largest markets. Pharma revenue grew 6% in the quarter, including another period of low-double-digit growth in biotech, led by large-cap customers. Small molecule pharma grew in the low single digits.

AutoZone's Pullback Sets Up a Long-Term Buying OpportunityChemicals and advanced materials grew 8%, helped by semiconductor demand and chemical capital spending in the Americas. Diagnostics and clinical grew 11%, driven by cancer diagnostics offerings. Environmental and forensics grew 13%, with forensics revenue up more than 50% due to a Transportation Security Administration airport security contract and competitive tender wins in Asia and Europe.

Food declined 3%, which management attributed to funding delays in China and India. Academia and government declined 5%, in line with Agilent’s expectations.

CFO Adam Elinoff said revenue growth was strongest in the Americas, where sales rose 11%. Europe and Asia excluding China grew in the high single digits. China declined 9% in the quarter, though Elinoff said China was roughly flat for the first half of the year, in line with the company’s full-year expectations.

Instrument Replacement Cycle and Product Launches Support Growth Agilent reported high-single-digit instrument revenue growth, including low-double-digit growth in LC and LC-MS and in GC. McDonnell said replacement cycle momentum and share gains tied to products such as the Infinity III LC and the 8850 GC helped drive results.

“Our commercial excellence delivered a book-to-bill above one again this quarter, marking the ninth consecutive quarter where instrument orders met or exceeded revenue,” McDonnell said.

The company also highlighted several upcoming launches at the American Society for Mass Spectrometry Annual Conference in San Diego. These include the 9500 Triple Quadrupole ICP-MS, upgraded flagship gas chromatographs and new Altura LC columns aimed at workflows for protein and peptide therapeutics, large oligos, gene therapy and vaccines.

McDonnell said the 9500 ICP-MS was developed in response to customer feedback around throughput, workflow complexity and operating costs. He also said Ignite helped accelerate the launch by a full quarter through focused resource allocation and cross-functional execution.

On the software side, Agilent is expanding OpenLab CDS with version 3.0, which McDonnell said provides a unified platform for chromatography, mass spectrometry and spectroscopy systems across the portfolio, including high-resolution mass spectrometry for the first time.

Ignite Operating System Drives Margins and Pricing Management repeatedly cited Ignite as a driver of both revenue and margin performance. McDonnell said strategic pricing delivered about 200 basis points of pricing in the second quarter, putting Agilent on track to exceed its initial full-year goal of 100 basis points.

He also said Agilent had fully mitigated the operating profit impact of incremental tariffs that began in late spring through manufacturing moves and targeted price adjustments. The company’s tariff task force has also helped develop a playbook for navigating trade and geopolitical challenges, including the current Middle East conflict.

Elinoff said gross margin rose 90 basis points year over year to 55%, helped by volume leverage, Ignite momentum and favorable regional mix. Operating margin expanded 130 basis points to 26.4%, ahead of guidance.

In response to an analyst question on margins, Elinoff said the margin beat was driven by Ignite, including pricing, execution and structural improvements in operations, as well as procurement productivity, volume leverage and geographic mix.

Agilent also reported $277 million in operating cash flow for the quarter and $76 million in capital expenditures. The company repurchased $65 million of shares and paid $72 million in dividends, ending the quarter with a net leverage ratio of 0.7 turns.

Guidance Raised for Fiscal 2026 Agilent raised its full-year fiscal 2026 revenue outlook to $7.39 billion to $7.49 billion on a reported basis, representing core growth of 4.5% to 6%. The midpoint of the core growth range increased by 30 basis points from the prior forecast. Currency is now expected to provide a 1.8% tailwind for the year.

The company also raised its full-year non-GAAP EPS forecast to $6.00 to $6.10, up $0.08 at the midpoint and representing expected earnings growth of 7% to 9%. Agilent increased its full-year operating margin expansion target to 85 basis points at the midpoint of revenue guidance.

For the third quarter, Agilent expects reported revenue of $1.83 billion to $1.85 billion, representing core growth of roughly 4.4% to 5.9%. Non-GAAP EPS is expected to be $1.48 to $1.50, up 8% to 9%.

Elinoff said the guidance does not include the impact of the planned Biocare acquisition or any benefit from potential tariff refunds. Agilent announced the Biocare acquisition in March, and McDonnell said Ignite is being used to prepare for integration ahead of closing.

Q&A Highlights: China, Diagnostics, Specialty CDMO and TSA During the analyst Q&A, McDonnell said Agilent views China as stable at roughly $300 million in revenue per quarter, despite the second-quarter decline. He said the company remains confident in a flattish full-year guide for China and expects mid-single- to high-single-digit long-term growth there.

On diagnostics, Simon May, president of the Life Sciences and Diagnostics Markets Group, said the Omnis family continues to ramp well across regions and that Agilent saw double-digit growth in both instruments and assays. He also cited continued demand in companion diagnostics, including antibody drug conjugates.

Asked about Agilent’s specialty CDMO business, recently rebranded as the Advanced Therapeutics Division, McDonnell said second-quarter growth was at the high end of high single digits. May said the company has “really strong visibility” into the second half and still expects mid-teens growth for fiscal 2026. He also said mechanical completion of the Train C build-out was achieved in the quarter, with revenue generation expected to begin next spring.

In forensics, Mike Zhang, president of the Applied Markets Group, discussed Agilent’s TSA security work. McDonnell said Agilent had previously called out a $9 million TSA win and recognized $5 million of that in the second quarter.

McDonnell closed by saying Agilent’s improved outlook reflects healthy demand in key markets, pricing realization, productivity gains and replacement cycle momentum. Longer term, he said the company’s diversified portfolio, services organization, innovation pipeline and Ignite operating system position it to “sustainably outperform the competition.”

About Agilent Technologies NYSE: AAgilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company's product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in Agilent Technologies Right Now?Before you consider Agilent Technologies, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agilent Technologies wasn't on the list.

While Agilent Technologies currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link to learn more about using beta to protect your portfolio.

Get This Free Report

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the introduction of OpenLab Sync, a new Lab Execution System (LES) that enables laboratories to digitally connect scientific workflows from method design through execution at the bench. OpenLab Sync extends Agilent's OpenLab laboratory informatics portfolio beyond traditional data and sample management, enabling guided, standardized, and traceable execution of laboratory work in regulated environments. As.

Agilent Technologies (A +0.22%) had a Thursday to remember, at least as far as its equity was concerned. The medical device and healthcare tech specialist posted its latest quarterly earnings report just after market close the previous day, and investors reacted very positively to it in Thursday's trading session. Their exuberance lifted the share price by nearly 17%.

Quite a healthy quarter Agilent booked revenue of $1.83 billion in its fiscal second quarter of 2026, up 10% year over year. Its net income not under generally accepted accounting principles (GAAP) saw a steeper rise, advancing by 14% to $423 million, or $1.49 per share.

Image source: Getty Images.

With those figures, Agilent beat the average analyst estimates on both the top and bottom lines. Prognosticators tracking the stock were modeling $1.8 billion in revenue and $1.41 per share in non-GAAP (adjusted) net income.

All three of Agilent's reporting units saw revenue growth during the quarter, hence the double-digit improvements. This was led by the Applied Markets Group with a 14% rise to $344 million. Close behind was the life sciences and diagnostics segment, which saw a 12% boost to $732 million. Finally, Agilent CrossLab's take increased by 6% to $759 million.

Today's Change

(

0.22

%) $

0.29

Current Price

$

129.84

Sunny future With these tailwinds at its back, Agilent management lifted the bottom end of its full-year 2026 revenue guidance; the range now stands at $7.39 billion to $7.49 billion. It made a more dramatic change to its adjusted net income projection, upping it to $6 to $6.10 per share from the previous estimate of $5.90 to $6.04.

It's impressive enough when a company posts substantial revenue gains in one or a few of its revenue streams; Agilent not only achieved this in the quarter but also delivered double-digit improvements in two of its three businesses. That, plus the notable bottom-line guidance raise, would give me plenty of confidence in Agilent's future.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the expanded use of PD-L1 IHC 22C3 pharmDx, Code GE006, for use on the Dako Omnis platform to aid in identifying patients in the United States with esophageal squamous cell carcinoma (ESCC)3, triple-negative breast cancer (TNBC)4, cervical cancer5, and gastric or gastroesophageal junction (GEJ) adenocarcinoma6, who may be eligible for treatment.

Agilent Technologies, Inc. (A) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Critical Information: SES AI's $0.63 Per-Share Collapse Quantifies Alleged Investor Damages as Phantom Deals and Circular Revenue Schemes Unravel

, /PRNewswire/ -- SueWallSt reminds purchasers of SES AI Corporation (NYSE: SES) securities of a pending securities class action. THE CASE: A class action seeks to recover damages for investors who purchased SES securities between January 29, 2025 and March 4, 2026. YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. See if you can recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

SES shares lost $0.63 per share on March 5, 2026, a single-day decline of 36.8%, closing at $1.08 after the company disclosed logistics failures and issued 2026 revenue guidance of $30 million to $35 million, roughly 35% to 42% below the $51.67 million Wall Street had expected. The lead plaintiff deadline is June 26, 2026.

The March 5, 2026 Market Repricing Event

The market's reaction was swift and severe. After SES AI's after-hours earnings call on March 4, 2026, investors learned for the first time that approximately $1.5 million in Q4 2025 revenue had been pushed into 2026 due to logistics constraints that management had not previously disclosed. More damaging still, the 2026 outlook confirmed what a December 2025 short-seller report had alleged: SES AI had materially overstated its commercial trajectory.

Benzinga reported on March 5 that the stock was "trading sharply lower" and that the guidance miss was "raising concerns about the pace of commercialization" across SES AI's energy storage, drone battery, and materials businesses.

How Alleged Artificial Inflation Was Removed From SES Shares

The complaint contends SES shares traded at artificially inflated prices throughout the Class Period because management promoted partnerships with entities that lacked meaningful operations and allegedly generated revenue through circular transactions involving its Molecular Universe platform. The lawsuit asserts that when the market absorbed the full scope of these issues, the artificial inflation was removed from the stock price in a single trading session.

Key indicators of the market impact include:

SES shares fell 36.8% in one day, erasing $0.63 per share of value 2026 revenue guidance missed analyst consensus by approximately $17 million to $22 million Remaining performance obligations had dropped 92% in Q3 2025, a metric not emphasized by management at the time The Company's Chief Science Officer sold 500,000 shares for over $1 million in proceeds across two sales in the months preceding the corrective disclosure. Full year 2025 revenue of $21 million landed at the low end of guidance only after logistics delays pushed $1.5 million into 2026 Calculate your potential recovery or call (888) SueWallSt.

"When companies fail to disclose material information, shareholders may suffer significant losses. The magnitude of SES AI's single-day decline reflects the gap between what was presented to the market and what was actually occurring inside the business." -- Joseph E. Levi, Esq.

Join the SES recovery action or contact Joseph E. Levi, Esq. at (888) SueWallSt.

ABOUT SUEWALLST -- Over the past 20 years, SueWallSt has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, SueWallSt has ranked in ISS Securities Class Action Services' Top 50 Report. The last day to move for lead plaintiff is June 26, 2026.

Frequently Asked Questions About the SES Lawsuit

Q: How much did SES stock drop? A: Shares fell approximately 36.8%, a decline of $0.63 per share, after the company disclosed logistics constraints and issued 2026 revenue guidance well below the $51.67 million analysts expected. Investors who purchased shares during the Class Period at artificially inflated prices may be entitled to compensation.

Q: What specific misstatements does the SES lawsuit allege? A: The complaint alleges SES AI made materially false or misleading statements regarding its business partnerships, revenue legitimacy, Molecular Universe platform demand, and logistics conditions during the Class Period. When the true state of affairs was revealed, the stock price declined sharply.

Q: What do SES investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What if I already sold my SES shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the Class Period and sold at a loss may still participate.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: How long will the lawsuit take to resolve? A: Securities class actions typically take two to four years from initial filing to resolution.

Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting SueWallSt before June 26, 2026 ensures your losses are considered.

CONTACT:

SueWallSt
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

Alert: Claims Focus on Alleged Failures in Internal Controls Over Confidential Information and Tax Compliance That Cost POET Investors $7.15 Per Share

, /PRNewswire/ -- SueWallSt reminds purchasers of POET Technologies Inc. (NASDAQ: POET) securities of a pending securities class action.

THE CASE: A class action seeks to recover damages for investors who purchased POET securities between April 1, 2026 and April 27, 2026.

YOUR OPTIONS: You may be entitled to compensation without payment of any out-of-pocket fees. Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at [email protected] or (888) SueWallSt.

POET shares collapsed 47.3%, losing $7.15 per share, after the Company disclosed on April 27, 2026 that its largest customer cancelled all purchase orders. Investors have until June 29, 2026 to seek lead plaintiff status.

How a Photonics Company's Internal Failures Allegedly Destroyed Its Most Important Customer Relationship

A photonic chip packaging company cannot grow without protecting the confidential relationships that generate its revenue. POET Technologies designs optical interposer solutions for AI and data center applications. The complaint recounts that the Company generated just $2.3 million in total revenue since 2020, making every customer relationship existentially important. The lawsuit contends that internal controls failed at two critical junctures: managing confidential customer information and accurately assessing international tax obligations.

The Alleged NDA Breach That Ended the Celestial AI Revenue Stream

As detailed in the action, the Company's CFO appeared in a public social media interview on April 21, 2026 and disclosed specific purchase order details, shipping timelines, and the supplier relationship with Marvell Semiconductor (which had acquired Celestial AI). The filing states that this disclosure directly violated confidentiality obligations. On April 23, 2026, Marvell provided written notice that POET had breached its NDA. By April 27, 2026, every purchase order from Celestial AI was cancelled.

Alleged Internal Controls Failures by the Numbers

The Company's sole meaningful near-term revenue source, Celestial AI purchase orders first disclosed in April 2023, was destroyed by the alleged NDA breach POET reported a net loss equal to negative 5,858% of its $2.3 million cumulative revenue since 2020 Shares outstanding surged 303% from 38 million to 153 million between late 2022 and early 2026, underscoring the Company's dependence on equity raises rather than product sales The 2025 Annual Report's SOX certifications attested to disclosure of all fraud and material changes to internal controls, yet the lawsuit chronicles that management failed to prevent confidential information from being broadcast on social media POET's own risk factor language acknowledged the Company "may be treated as a PFIC," yet the complaint alleges this disclosure materially understated the likelihood and consequences The Tax Compliance Gap

Separately, the action claims POET's internal processes failed to accurately assess and disclose the severity of its Passive Foreign Investment Company status. It is alleged that the 2025 Annual Report used hedging language ("we believe that we may be treated as a PFIC") when the Company's financial profile, dominated by passive income with negligible operating revenue, made PFIC classification near-certain. U.S. shareholders face punitive tax rates and compounding IRS interest when holding PFIC shares without proper elections.

See if you can recover losses or call (888) SueWallSt.

"The complaint raises serious questions about whether investors received accurate information about the operational safeguards protecting POET's most critical business relationships and tax obligations." -- Joseph E. Levi, Esq.

Calculate your potential recovery or contact Joseph E. Levi, Esq. at (888) SueWallSt.

ABOUT SUEWALLST -- Ranked in ISS Securities Class Action Services' Top 50 Report for seven consecutive years, SueWallSt is a nationally recognized leader in shareholder rights litigation. With a team of over 70 professionals, the firm has recovered hundreds of millions of dollars for investors.

Frequently Asked Questions About the POET Lawsuit

Q: Who is eligible to join the POET investor lawsuit? A: Investors who purchased POET stock or securities between April 1, 2026 and April 27, 2026 and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses, not on whether you still hold the shares.

Q: How much did POET stock drop? A: Shares fell approximately 47.3%, a decline of $7.15 per share, after the Company disclosed the cancellation of all Celestial AI purchase orders due to an alleged NDA breach. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.

Q: What do POET investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact SueWallSt for a free, no-obligation evaluation at [email protected] or (888) SueWallSt. No immediate action is required to remain eligible as a class member.

Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Q: What if I already sold my POET shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.

Q: What is the POET lead plaintiff deadline? A: The deadline to apply for lead plaintiff appointment is June 29, 2026. This deadline applies only to investors seeking to serve as lead plaintiff. Class members who do not apply may still participate in any recovery without taking action before this date.

CONTACT:

SueWallSt
Joseph E. Levi, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
[email protected]
Tel: (888) SueWallSt
Fax: (212) 363-7171

SOURCE SueWallSt.com

Vanguard FTSE Canadian High Dividend Yield Idx ETF (VDY:CA) is rated HOLD, offering reliable income but high sector concentration in financials and energy. VDY's strategy prioritizes forecast dividend yield over growth or diversification, resulting in strong historical returns but elevated concentration risk. With a 3.17% yield and 0.22% expense ratio, VDY suits income-focused investors comfortable with sector bets, but lacks upside catalysts for new buyers.